Filtered By:
Condition: Multiple Sclerosis
This page shows you your search results in order of relevance. This is page number 17.
Order by Relevance | Date
Total 1656 results found since Jan 2013.
The reliability and validity of the Timed Up and Go as a clinical tool in individuals with and without disabilities across a lifespan: a systematic review.
Conclusions: Based on the literature assessed, the Timed Up and Go is clinically applicable and reliable across multiple populations. The Timed Up and Go has a wide variety of clinical use making it a diverse measure that should be considered when choosing an outcome an activity based outcome measure. However, there are some limitations in the validity of the utilization of the Timed Up and Go to some populations due to a lack of data and/or poor choice of comparison outcome measures when assessing validity. Additional research is needed for young to middle aged adults. IMPLICATIONS FOR REHABILITATION Outcome measures are ...
Source: Disability and Rehabilitation - October 25, 2019 Category: Rehabilitation Authors: Christopher A, Kraft E, Olenick H, Kiesling R, Doty A Tags: Disabil Rehabil Source Type: research
Associations Between Two Single-Nucleotide Polymorphisms in NINJ2 Gene and Risk of Psychiatric Disorders
AbstractNINJ2 encodes a transmembrane protein that contributes in neurodevelopment and regeneration of neurons. Single-nucleotide polymorphisms (SNPs) within this gene have been associated with Alzheimer ’s disease, ischemic stroke, and multiple sclerosis. The rs11833579 and rs3809263 SNPs have been associated with risk of ischemic stroke in Iranian population. While theNINJ2 rs12425791 has been with risk of ischemic stroke in East Asian population, the rs11833579 has not been associated with this condition either in East Asian population or Chinese Han population. In the current project, we genotyped rs11833579 and rs38...
Source: Journal of Molecular Neuroscience - December 22, 2019 Category: Neuroscience Source Type: research
Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018).
, Paulus W, Poulet E, Quartarone A, Rachid F, Rektorová I, Rossi S, Sahlsten H, Schecklmann M, Szekely D, Ziemann U
Abstract
A group of European experts reappraised the guidelines on the therapeutic efficacy of repetitive transcranial magnetic stimulation (rTMS) previously published in 2014 [Lefaucheur et al., Clin Neurophysiol 2014;125:2150-206]. These updated recommendations take into account all rTMS publications, including data prior to 2014, as well as currently reviewed literature until the end of 2018. Level A evidence (definite efficacy) was reached for: high-frequency (HF) rTMS of the primary motor corte...
Source: Clinical Neurophysiology - December 26, 2019 Category: Neurology Authors: Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, Filipović SR, Grefkes C, Hasan A, Hummel FC, Jääskeläinen SK, Langguth B, Leocani L, Londero A, Nardone R, Nguyen JP, Nyffeler T, Oliveira-Maia AJ, Oliviero A, Padberg F, Palm Tags: Clin Neurophysiol Source Type: research
Characteristics of peer-based interventions for individuals with neurological conditions: a scoping review
CONCLUSION: Various peer-based interventions exist, each with its own definition of what it means to be a peer. Research using rigorous methodology is needed to determine the most effective interventions. Clear definitions of each program component are needed to better understand the outcomes and mechanism of action within each intervention.IMPLICATIONS FOR REHABILITATIONRehabilitation services can draw on various peer support interventions to add experiential knowledge and support based on shared experience to enhance outcomes.Fulfilling the role of peer mentor may be beneficial and could be encouraged as part of the reha...
Source: Disability and Rehabilitation - January 27, 2022 Category: Rehabilitation Authors: Sarah Aterman Setareh Ghahari Dorothy Kessler Source Type: research
E-248 Postpartum vertebral artery dissections: a report of 7 cases and literature review
ConclusionA limited cohort of 33 ppVADs exist in the literature. This study contributes 7 additional cases and suggests that, despite heterogenous management of ppVAD, the resulting outcomes were favorable.Disclosures V. Lazarov: None. A. Monteiro: None. F. Almayman: None. M. Waqas: None. J. Cappuzzo: None. E. Levy: None. A. Siddiqui: None.
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Lazarov, V., Monteiro, A., Almayman, F., Waqas, M., Cappuzzo, J., Levy, E., Siddiqui, A. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research
HMGB1 in nervous system diseases: A common biomarker and potential therapeutic target
High-mobility group box-1 (HMGB1) is a nuclear protein associated with early inflammatory changes upon extracellular secretion expressed in various cells, including neurons and microglia. With the progress of research, neuroinflammation is believed to be involved in the pathogenesis of neurological diseases such as Parkinson's, epilepsy, and autism. As a key promoter of neuroinflammation, HMGB1 is thought to be involved in the pathogenesis of Parkinson's disease, stroke, traumatic brain injury, epilepsy, autism, depression, multiple sclerosis, and amyotrophic lateral sclerosis. However, in the clinic, HMGB1 has not been de...
Source: Frontiers in Neurology - October 31, 2022 Category: Neurology Source Type: research
Relationship between motor performance and cortical activity of older neurological disorder patients with dyskinesia using fNIRS: A systematic review
Conclusion: Most of the reviewed studies reported poor motor performance and increased cortical activation of PD, stroke and multiple sclerosis older patients. The external motor performance such as step speed were analyzed only. The design and results were not comprehensive and profound. More than 5 weeks walking training or physiotherapy can contribute to motor function promotion as well as cortices activation of PD and stroke patients. Thus, further study is needed for more statistical analysis on the relationship between motor performance and activation of the motor-related cortex. More different type and program spor...
Source: Frontiers in Physiology - March 27, 2023 Category: Physiology Source Type: research
The NOX1/4 Inhibitor GKT136901 as Selective and Direct Scavenger of Peroxynitrite.
Abstract
NADPH oxidases (NOX), catalyzing the reduction of molecular oxygen to form the superoxide radical anion (.O2-) and hydrogen peroxide (H2O2), are involved in several pathological conditions, such as stroke, diabetes, atherosclerosis, but also in chronic neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, or multiple sclerosis. GKT136901 is a novel NOX-1/4 inhibitor with potential application in the areas of diabetic nephropathy, stroke, or neurodegeneration. In the present study, we investigated additional pharmacological activities of the compound with respect to direct free radic...
Source: Current Medicinal Chemistry - July 8, 2013 Category: Chemistry Authors: Schildknecht S, Weber A, Gerding HR, Pape R, Robotta M, Drescher M, Marquardt A, Daiber A, Ferger B, Leist M Tags: Curr Med Chem Source Type: research
Membrane‐type 1 metalloproteinase is upregulated in microglia/brain macrophages in neurodegenerative and neuroinflammatory diseases
We previously reported that glioma cells induce the expression of membrane‐type 1 metalloproteinase (MT1‐MMP or MMP‐14) in tumor‐associated microglia/macrophages and promote tumor growth, whereas MMP‐14 expression in microglia under physiological conditions is very low. Here, we show that the increase in MMP‐14 expression is also found in microglia/macrophages associated with neurodegenerative and neuroinflammatory pathologies in mouse models as well as in human biopsies or post‐mortem tissue. We found that microglial/macrophage MMP‐14 expression was upregulated in Alzheimer's disease tissue, in active lesi...
Source: Journal of Neuroscience Research - December 10, 2013 Category: Neuroscience Authors: Anika Langenfurth, Jan Leo Rinnenthal, Katyayni Vinnakota, Vincent Prinz, Anne‐Sophie Carlo, Christine Stadelmann, Volker Siffrin, Susann Peaschke, Matthias Endres, Frank Heppner, Rainer Glass, Susanne A. Wolf, Helmut Kettenmann Tags: Research Article Source Type: research
Taking Neurology to the Underserved - A Pilot Initiative in an Urban Homebound Program (P6.007)
CONCLUSIONS: Our pilot program highlights types of chronic neurologic illnesses afflicting the homebound population, treatment interventions utilized, and clinical challenges encountered. By considering the real-world intersection of disease and living environment, trainees gained perspective on the debilitating impact of neurological illness on homebound patients. This pilot program reveals the need and feasibility of neurological home based care as an important clinical, educational, and palliative paradigm.Disclosure: Dr. Ramdhani has nothing to disclose. Dr. Fabian has received personal compensation for activities with...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Ramdhani, R., Fabian, M., Wajnberg, A., DeCherrie, L., Krieger, S. Tags: General Neurology V Source Type: research
Randomized Controlled Trial of CI Therapy for Progressive MS: Increased Real-World Function and Neuroplasticity on MRI (S23.007)
CONCLUSIONS: CI therapy appears to be efficacious for improving real-world arm use in progressive hemiparetic MS and significantly increases cortical grey matter structural plasticity. Together, these findings suggest that CI therapy, but not CAM, can counteract the progressive functional loss and CNS degeneration of progressive MS.Supported by: National MS Society grant RG 4221 and NIH grant HD061767.Disclosure: Dr. Mark has nothing to disclose. Dr. Taub has nothing to disclose. Dr. Uswatte has nothing to disclose. Dr. Cutter has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals Inc., Cleve...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Mark, V., Taub, E., Uswatte, G., Cutter, G., Morris, D., McKay, S., Bowman, M., Haddad, M., Rickards, T., Sterling, C. Tags: MS and CNS Inflammatory Disease: Novel Therapeutics Source Type: research
Dextromethorphan and Quinidine for Treatment of Pseudobulbar Affect (PBA): Time Course of PBA Episode Remission (S31.007)
Conclusions: Approximately half of patients receiving DMQ-20 experienced PBA episode remission during this 12-week pivotal trial. Significant differences vs. placebo in the percentage of patients entering remission emerged early (Week 1) and remained significant in subsequent trial weeks.Study Supported by: Avanir Pharmaceuticals, Inc.Disclosure: Dr. Formella has received personal compensation for activities with Avanir Pharmaceuticals Inc. as an employee. Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Insti...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Formella, A., Brooks, B. Tags: General Neurology I Source Type: research
